Polynucleotides encoding engineered tyrosine ammonia lyase variants

US10287567B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10287567-B2
Application numberUS-201715432429-A
CountryUS
Kind codeB2
Filing dateFeb 14, 2017
Priority dateApr 16, 2014
Publication dateMay 14, 2019
Grant dateMay 14, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides engineered tyrosine ammonia-lyase (TAL) polypeptides and compositions thereof. In some embodiments, the engineered TAL polypeptides have been optimized to provide enhanced catalytic activity while reducing sensitivity to proteolysis and increasing tolerance to acidic pH levels. The invention also provides methods for utilization of the compositions comprising the engineered TAL polypeptides for therapeutic and industrial purposes.

First claim

Opening claim text (preview).

What is claimed is: 1. A polynucleotide encoding a recombinant tyrosine ammonia lyase, wherein said recombinant tyrosine ammonia lyase comprises an amino acid sequence comprising at least 90% sequence identity to SEQ ID NO:14, and wherein said recombinant tyrosine ammonia lyase comprises a mutation at position 107. 2. The polynucleotide encoding the recombinant tyrosine ammonia lyase of claim 1 , wherein said tyrosine ammonia lyase further comprises at least one additional mutation at position 18, 47, 54, 59, 64, 73, 77, 88, 91, 93, 95, 97, 108, 214, 219, 222, 253, 304, 307, 315, 364, 367, 389, 394, 396, 400, 401, 423, 447, 453, 462, 490, 500, 503, 521, 550, 554, 564, and/or 565, and wherein the positions correspond to SEQ ID NO: 14. 3. The polynucleotide encoding the recombinant tyrosine ammonia lyase of claim 1 , wherein said recombinant tyrosine ammonia lyase is thermostable. 4. The polynucleotide encoding the recombinant tyrosine ammonia lyase of claim 1 , wherein said recombinant tyrosine ammonia lyase is resistant to proteolysis. 5. The polynucleotide encoding the recombinant tyrosine ammonia lyase of claim 4 , wherein said recombinant tyrosine ammonia lyase is resistant to at least one digestive tract protease. 6. The polynucleotide encoding the recombinant tyrosine ammonia lyase of claim 5 , wherein said digestive tract protease is selected from chymotrypsin, trypsin, carboxypeptidases, and elastases. 7. The polynucleotide encoding the recombinant tyrosine ammonia lyase of claim 1 , wherein said recombinant tyrosine ammonia lyase is acid stable. 8. The polynucleotide encoding the recombinant tyrosine ammonia lyase of claim 1 , wherein said recombinant tyrosine ammonia lyase is a deimmunized tyrosine ammonia lyase. 9. The polynucleotide encoding the recombinant tyrosine ammonia lyase of claim 1 , wherein said recombinant tyrosine ammonia lyase is purified. 10. The recombinant polynucleotide sequence of claim 1 , wherein said polynucleotide sequence is codon-optimized. 11. An expression vector comprising the recombinant polynucleotide sequence of claim 1 . 12. The expression vector of claim 11 , wherein said recombinant polynucleotide sequence is operably linked to a control sequence. 13. The expression vector of claim 12 , wherein said control sequence is a promoter. 14. The expression vector of claim 13 , wherein said promoter is a heterologous promoter. 15. A host cell comprising the expression vector of claim 11 . 16. The host cell of claim 15 , wherein said host cell is prokaryotic or eukaryotic. 17. The host cell of claim 16 , wherein said host cell is Escherichia coli. 18. A method of producing a tyrosine ammonia lyase variant, comprising culturing said host cell of claim 15 , under conditions that said tyrosine ammonia lyase encoded by said recombinant polynucleotide is produced. 19. The method of claim 18 , further comprising the step of recovering said tyrosine ammonia lyase. 20. The method of claim 19 , further comprising the step of purifying said tyrosine ammonia lyase.

Assignees

Inventors

Classifications

  • having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin · CPC title

  • Lyases (4) · CPC title

  • C12N9/88Primary

    Lyases (4.) · CPC title

  • Tyrosine ammonia-lyase (4.3.1.23) · CPC title

  • Tyrosine; 3,4-Dihydroxyphenylalanine · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10287567B2 cover?
The present invention provides engineered tyrosine ammonia-lyase (TAL) polypeptides and compositions thereof. In some embodiments, the engineered TAL polypeptides have been optimized to provide enhanced catalytic activity while reducing sensitivity to proteolysis and increasing tolerance to acidic pH levels. The invention also provides methods for utilization of the compositions comprising the …
Who is the assignee on this patent?
Codexis Inc
What technology area does this patent fall under?
Primary CPC classification C12N9/88. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).